Immunotherapy in ovarian cancer: we are not there yet
Mené dans 24 pays sur 566 patientes atteintes d'un cancer de l'ovaire réfractaire ou résistant aux sels de platine, cet essai à 3 bras de phase III compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de la doxorubicine liposomale pégylée en monothérapie et de l'avélumab, dispensé seul ou en combinaison avec la doxorubicine liposomale pégylée
With the disappointment brought by modest results of trials testing single-agent immunecheckpoint inhibitors in recurrent ovarian cancer, renewed optimism arose around the possibility that combination treatments would deliverthe positive results the community was waiting for. Surely, there would be a way toenhance the activity of immunotherapy in recurrent ovarian cancer, a setting in whichprogress had remained elusive. In other tumour types, chemotherapy had been shownto induce antigen presentation, priming tumour cells to become receptive to the immuneattack triggered by PD-L1 inhibitors and yielding improved clinical outcomes. Those data revitalising the field of immunotherapy in solid tumours provided therationale for also testing immune checkpoint inhibitors with chemotherapy in ovariancancer.
The Lancet Oncology , commentaire, 2020